In the United States, the percentage of adults who stated they had ever had trouble in their family due to drug abuse rose from 19 percent in 1995 to 32 percent in 2021. This statistic shows the percentage of U.S. adults who reported drug abuse had ever caused trouble in their family from 1995 to 2021.

In 2019, around 27 percent of male adults in the United States who were assessed for substance use treatment reported having severe legal problems. This statistic illustrates the percentage of adults in the United States assessed for substance use treatment that had severe biopsychosocial problems as of 2019, by gender.

Marijuana is by far the most used illicit drug in the United States, with over 64 million people using this drug in 2024. The second most used drug at that time was cocaine, followed by methamphetamine and ecstasy. The United States has had a complicated history with drugs, from fighting a “War on Drugs” starting in the 1970s, to seeing the legalisation of marijuana in many states, and experiencing an ongoing nationwide opioid overdose epidemic. Recreational marijuana Although marijuana is still illegal under federal law, 21 states have legalized the recreational use of marijuana. This legalization has opened a new and thriving market in these states. It is estimated that sales of legal cannabis will reach around 25 billion U.S. dollars by the year 2025. Although support for the legalization of marijuana has not always been strong, now around 68 percent of U.S. adults believe it should be made legal. The opioid epidemic The opioid epidemic describes a rise in overdose deaths in the U.S. due to prescription opioids, heroin, and illegally manufactured synthetic opioids such as fentanyl. The epidemic stems from misleading information from pharmaceutical companies concerning the dangers of opioids such as oxycontin, overprescribing of opioids from physicians, and an influx of easily accessible heroin and highly potent synthetic opioids. In 2022, there were around 81,806 deaths from opioid overdose in the United States.

In 2022, the drug overdose death rate for male adolescents in the U.S. was three per 100,000 adolescents. Between 2018 and 2022, the drug overdose death rate for adolescents in the United States more than doubled for males and females. This statistic illustrates the drug overdose death rate among adolescents in the United States from 2018 to 2022, by sex (per 100,000 adolescents).

This series measures the prevalence and correlates of drug use in the United States. The surveys are designed to provide quarterly, as well as annual, estimates. Information is provided on the use of illicit drugs, alcohol, tobacco, and nonmedical use of prescription drugs among members of United States households aged 12 and older. Questions include age at first use, as well as lifetime, annual, and past-month usage for the following drug classes: cannabis, cocaine, hallucinogens, heroin, inhalants, alcohol, tobacco, nonmedical use of prescription drugs including psychotherapeutics, and polysubstance use. Respondents were also asked about their knowledge of drugs, perceptions of the risks involved, population movement, and sequencing of drug use. Fifty-seven percent of respondents were asked specific questions about their perceptions of the consequences of marijuana and alcohol use. The other 43 percent were asked about heroin use among friends. Demographic data include sex, race, age, ethnicity, marital status, educational level, job status, income level, and household composition. This study has 1 Data Set.

Abstract (en): The National Survey on Drug Use and Health (NSDUH) series (formerly titled National Household Survey on Drug Abuse) primarily measures the prevalence and correlates of drug use in the United States. The surveys are designed to provide quarterly, as well as annual, estimates. Information is provided on the use of illicit drugs, alcohol, and tobacco among members of United States households aged 12 and older. Questions included age at first use as well as lifetime, annual, and past-month usage for the following drug classes: marijuana, cocaine (and crack), hallucinogens, heroin, inhalants, alcohol, tobacco, and nonmedical use of prescription drugs, including pain relievers, tranquilizers, stimulants, and sedatives. The survey covered substance abuse treatment history and perceived need for treatment, and included questions from the Diagnostic and Statistical Manual (DSM) of Mental Disorders that allow diagnostic criteria to be applied. The survey included questions concerning treatment for both substance abuse and mental health related disorders. Respondents were also asked about personal and family income sources and amounts, health care access and coverage, illegal activities and arrest record, problems resulting from the use of drugs, and needle-sharing. Questions introduced in previous administrations were retained in the 2006 survey, including questions asked only of respondents aged 12 to 17. These "youth experiences" items covered a variety of topics, such as neighborhood environment, illegal activities, drug use by friends, social support, extracurricular activities, exposure to substance abuse prevention and education programs, and perceived adult attitudes toward drug use and activities such as school work. Several measures focused on prevention-related themes in this section. Also retained were questions on mental health and access to care, perceived risk of using drugs, perceived availability of drugs, driving and personal behavior, and cigar smoking. Questions on the tobacco brand used most often were introduced with the 1999 survey. Background information includes gender, race, age, ethnicity, marital status, educational level, job status, veteran status, and current household composition. Due to unequal selection probabilities at multiple stages of sample selection and various adjustments, such as those for nonresponse and poststratification, the 2006 NSDUH sample design is not self-weighting. Analysts are advised to use the final sample weight when attempting to use the 2006 NSDUH data to draw inferences about the target population or any subdomains of the target population. All estimates published in SAMHSA reports (such as the results from the 2006 NSDUH) are weighted using the final analysis weight for the full sample (ANALWT). For the public use file, the corresponding final sample weight is denoted as ANALWT_C, with the "C" denoting confidentiality protection. This sample weight represents the total number of target population persons each record on the file represents. Note that the sum of ANALWT_C, over all records on the data file, represents an estimate of the total number of people in the target population. ICPSR data undergo a confidentiality review and are altered when necessary to limit the risk of disclosure. ICPSR also routinely creates ready-to-go data files along with setups in the major statistical software formats as well as standard codebooks to accompany the data. In addition to these procedures, ICPSR performed the following processing steps for this data collection: Performed consistency checks.; Created online analysis version with question text.; Checked for undocumented or out-of-range codes.. Response Rates: Strategies for ensuring high rates of participation resulted in a weighted screening response rate of 90 percent and a weighted interview response rate for the CAI of 74 percent. (Note that these response rates reflect the original sample, not the subsampled data file referenced in this document.) The civilian, noninstitutionalized population of the United States aged 12 and older, including residents of noninstitutional group quarters such as college dormitories, group homes, shelters, rooming houses, and civilians dwelling on military installations. A multistage area probability sample for each of the 50 states and the District of Columbia was used since 1999. The 2005 NSDUH is the first survey in a coordinated five-year sample design. Although there is no...

In 2021/2022, the states with the highest share of people who had used cocaine in the past year were Colorado, Vermont, the District of Columbia, Rhode Island and Massachusetts. In Colorado, around 3.06 percent of the population were estimated to have used cocaine in the past year at that time, compared to the U.S. average of 1.95 percent. The states with the lowest past-year cocaine consumption rates were New Hampshire and Wyoming. Cocaine use in the United States As of 2022, cocaine was the second most used illicit drug in the United States, behind marijuana. At that time around 42.2 million people in the U.S. had used cocaine at least once in their lifetime. In comparison, around 29.5 million people reported using LSD in their lifetime and 22.1 million had used ecstasy. In 2022, almost 5.2 million people were estimated to have used cocaine in the past year. How many people in the U.S. die from cocaine every year? The number of drug poisoning deaths involving cocaine has increased significantly over the past couple decades. In 2021, there were around 24,486 overdose deaths involving cocaine, compared to just 3,800 in the year 1999. However, it is important to note that many overdose deaths involving cocaine also involve other drugs, namely opioids. The increase in overdose deaths involving cocaine is directly related to the ongoing opioid epidemic in the United States. Rates of overdose death involving cocaine are twice as high for men than women, but death rates for both men and women have increased in recent years.

From June 2024 to May 2025, the rate of emergency department (ED) visits for heroin-involved nonfatal overdose among those aged between 35 and 44 was 2.5 per 10,000 ED visits, highest across all age groups. Meanwhile, the rate of ED visits for heroin-involved nonfatal overdose among those aged between 45 and 54 was 2.1 per 10,000 ED visits.

A study conducted in 2022 in the United States found that individuals who identified as bisexual, gay, or lesbian were more prone to use illicit drugs than heterosexuals. Approximately ** percent of bisexual adults in the U.S. indicated having used illegal drugs a month prior to the survey, the largest share relative to other groups. This statistic illustrates the percentage of adults who reported illicit drug use in the past month in the U.S. as of 2022, by sexual identity.

In 2024, it was estimated that over **** million people in the United States had used cocaine at some point in their life. The number of people in the United States who stated they had used cocaine in the past month has fluctuated over the past decade, but over *** million people reported they had used cocaine in the past month as of 2023. Cocaine use among teens The percentage of U.S. students in grades *, **, and ** that had used cocaine in their lifetime has gradually decreased since 1999. At that time, around *** percent of students stated they had used cocaine in their lifetime, while in 2021 just *** percent of students said so. Perhaps unsurprisingly, perceived availability of cocaine among **** graders has also decreased over the past couple decades, with about ** percent of **** graders stating cocaine was “fairly easy” or “very easy” to get in 2021, compared to almost ** percent who reported it was easy to get in 1990. The most common illicit drugs U.S. students in grades *, **, and ** reported having used in their lifetime were marijuana, inhalants, and hallucinogens such as LSD and mushrooms. Deaths from cocaine In 2020, there were ****** drug poisoning deaths involving cocaine in the United States. The number of overdose deaths involving cocaine has increased significantly over the past few years as part of the ongoing opioid epidemic. Although, it is possible to die of an overdose just from using cocaine, many overdose deaths in the U.S. that involved cocaine also involved the use of opioids. The rate of overdose deaths involving cocaine is almost ***** times higher among men than women, but both have seen increases in the rate of overdose death in recent years. Considering race and ethnicity, the rate of overdose deaths involving cocaine is by far highest among black, non-Hispanics and lowest among Asian/Pacific Islander, non-Hispanics.

BackgroundInjection drug use provides an efficient mechanism for transmitting bloodborne viruses, including human immunodeficiency virus (HIV) and hepatitis C virus (HCV). Effective targeting of resources for prevention of HIV and HCV infection among persons who inject drugs (PWID) is based on knowledge of the population size and disparity in disease burden among PWID. This study estimated the number of PWID in the United States to calculate rates of HIV and HCV infection.MethodsWe conducted meta-analysis using data from 4 national probability surveys that measured lifetime (3 surveys) or past-year (3 surveys) injection drug use to estimate the proportion of the United States population that has injected drugs. We then applied these proportions to census data to produce population size estimates. To estimate the disease burden among PWID by calculating rates of disease we used lifetime population size estimates of PWID as denominators and estimates of HIV and HCV infection from national HIV surveillance and survey data, respectively, as numerators. We calculated rates of HIV among PWID by gender-, age-, and race/ethnicity.ResultsLifetime PWID comprised 2.6% (95% confidence interval: 1.8%–3.3%) of the U.S. population aged 13 years or older, representing approximately 6,612,488 PWID (range: 4,583,188–8,641,788) in 2011. The population estimate of past-year PWID was 0.30% (95% confidence interval: 0.19 %–0.41%) or 774,434 PWID (range: 494,605–1,054,263). Among lifetime PWID, the 2011 HIV diagnosis rate was 55 per 100,000 PWID; the rate of persons living with a diagnosis of HIV infection in 2010 was 2,147 per 100,000 PWID; and the 2011 HCV infection rate was 43,126 per 100,000 PWID.ConclusionEstimates of the number of PWID and disease rates among PWID are important for program planning and addressing health inequities.

Data on drug overdose death rates, by drug type and selected population characteristics. Please refer to the PDF or Excel version of this table in the HUS 2019 Data Finder (https://www.cdc.gov/nchs/hus/contents2019.htm) for critical information about measures, definitions, and changes over time. SOURCE: NCHS, National Vital Statistics System, numerator data from annual public-use Mortality Files; denominator data from U.S. Census Bureau national population estimates; and Murphy SL, Xu JQ, Kochanek KD, Arias E, Tejada-Vera B. Deaths: Final data for 2018. National Vital Statistics Reports; vol 69 no 13. Hyattsville, MD: National Center for Health Statistics.2021. Available from: https://www.cdc.gov/nchs/products/nvsr.htm. For more information on the National Vital Statistics System, see the corresponding Appendix entry at https://www.cdc.gov/nchs/data/hus/hus19-appendix-508.pdf.

Musculoskeletal Drugs Market Outlook

According to our latest research, the global musculoskeletal drugs market size reached USD 73.5 billion in 2024, driven by the increasing prevalence of musculoskeletal disorders worldwide. The market is expected to expand at a CAGR of 5.1% during the forecast period, reaching a value of USD 114.2 billion by 2033. This robust growth is underpinned by the rising incidence of chronic conditions such as arthritis, osteoporosis, and other degenerative bone and joint diseases, alongside advancements in drug development and delivery technologies.

One of the primary growth factors for the musculoskeletal drugs market is the rapidly aging global population. As the proportion of individuals aged 60 and above continues to climb, there is a corresponding surge in age-related musculoskeletal disorders, including osteoarthritis, rheumatoid arthritis, and osteoporosis. These conditions are particularly prevalent in developed economies, where improved healthcare infrastructure and longer life expectancy contribute to higher diagnosis and treatment rates. Moreover, the sedentary lifestyle adopted by many in both urban and rural settings has increased the risk of obesity, further exacerbating the prevalence of musculoskeletal disorders and, consequently, the demand for effective pharmacological interventions.

Another significant driver is the continuous innovation in drug development, particularly the emergence of biologics and targeted therapies. Biologics, disease-modifying antirheumatic drugs (DMARDs), and advanced corticosteroids offer improved efficacy and safety profiles compared to traditional therapies. The pharmaceutical industry’s investment in research and development has led to the introduction of novel therapeutics that address unmet clinical needs, reduce side effects, and provide better disease management. Additionally, the increasing awareness among patients and healthcare providers about the benefits of early diagnosis and treatment of musculoskeletal conditions is fueling the adoption of advanced musculoskeletal drugs across global markets.

The expansion of healthcare access and reimbursement policies, especially in emerging economies, is further propelling the musculoskeletal drugs market. Governments and private insurers are increasingly covering the costs of essential musculoskeletal medications, making them more accessible to larger segments of the population. This trend is particularly notable in Asia Pacific and Latin America, where rapid urbanization and improving healthcare infrastructure are closing the gap between demand and supply. Furthermore, the growing presence of online pharmacies and digital health platforms is enhancing the distribution and reach of musculoskeletal drugs, making it easier for patients to access these medications, even in remote or underserved areas.

From a regional perspective, North America continues to dominate the musculoskeletal drugs market, accounting for the largest share due to its advanced healthcare system, high disease prevalence, and strong focus on research and development. Europe follows closely, supported by robust reimbursement frameworks and a growing geriatric population. Meanwhile, the Asia Pacific region is witnessing the fastest growth, driven by increasing healthcare expenditure, rising awareness, and a large patient pool. Latin America and the Middle East & Africa, although smaller in market size, are expected to experience steady growth due to ongoing healthcare reforms and improved access to pharmaceuticals.

Drug Type Analysis

The musculoskeletal drugs market is segmented by drug type into Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), corticosteroids, muscle relaxants, disease-modifying antirheumatic drugs (DMARDs), biologics, and others. NSAIDs remain the most widely used class of drugs for managing pain and inflammation associated with musculoskeletal disorders. Their widespread availability, cost-effectiveness, and rapid onset of action make them a staple in both prescription and over-the-counter formulations. However, concerns regarding gastrointestinal and cardiovascular side effects have prompted the development of newer NSAIDs with improved safety profiles, further stimulating market growth.

Corticosteroids are another critical segment, primarily used for their potent anti-inflammatory and immunosuppressive properties. These drugs are often prescribed for acute flare-ups of conditions such a

Urinary Incontinence Drugs Market Outlook

According to our latest research, the global urinary incontinence drugs market size reached USD 4.7 billion in 2024, propelled by increasing prevalence of urinary disorders and growing awareness about treatment options. The market is expected to expand at a CAGR of 7.2% from 2025 to 2033, with the market size forecasted to reach approximately USD 8.8 billion by 2033. Key growth factors include an aging global population, higher diagnosis rates, and ongoing pharmaceutical innovation in the field of urology.

One of the primary growth drivers for the urinary incontinence drugs market is the rapidly aging global population. As individuals age, the risk of developing urinary incontinence increases significantly due to factors such as weakened pelvic muscles, chronic health conditions, and hormonal changes. This demographic shift is especially pronounced in developed regions like North America and Europe, where a substantial proportion of the population is over the age of 65. The rise in age-related incontinence cases has led to greater demand for effective pharmacological interventions, prompting pharmaceutical companies to invest in research and development of novel drug formulations. Additionally, the growing awareness about the impact of urinary incontinence on quality of life has led to increased healthcare-seeking behavior, further fueling market growth.

Another significant factor contributing to the expansion of the urinary incontinence drugs market is the advancement in drug delivery technologies and the introduction of new drug classes. The development of beta-3 agonists and improved anticholinergic agents has expanded the therapeutic arsenal available for managing different types of incontinence. These innovations have provided patients with more effective and better-tolerated treatment options, reducing the incidence of side effects commonly associated with older medications. Furthermore, the pharmaceutical industry’s focus on patient-centric drug development, including extended-release formulations and combination therapies, has enhanced medication adherence and therapeutic outcomes. This, in turn, has increased the adoption of urinary incontinence drugs across various patient demographics.

Healthcare infrastructure improvements and increased accessibility to medical care in emerging economies are also playing a pivotal role in market growth. Governments and healthcare organizations are implementing initiatives to raise awareness about urinary incontinence and reduce the stigma associated with the condition. This has led to higher diagnosis rates and a greater willingness among patients to seek medical treatment. The expansion of online and retail pharmacy channels has made urinary incontinence drugs more accessible, particularly in remote and underserved regions. These factors, combined with favorable reimbursement policies in certain countries, are expected to sustain the momentum of the urinary incontinence drugs market in the coming years.

From a regional perspective, North America currently dominates the urinary incontinence drugs market, accounting for the largest revenue share in 2024. This leadership is attributed to the region’s advanced healthcare infrastructure, high prevalence of chronic diseases, and robust pharmaceutical industry. Europe follows closely, supported by comprehensive healthcare coverage and a growing elderly population. However, the Asia Pacific region is anticipated to witness the fastest growth rate over the forecast period, driven by increasing healthcare expenditure, rising awareness, and improving access to medical care. Latin America and the Middle East & Africa are also expected to contribute to market growth, albeit at a comparatively moderate pace, as healthcare systems in these regions continue to develop.

Drug Type Analysis

The urinary incontinence drugs market is segmented by drug type into anticholinergics, beta-3 agonists, alpha blockers, topical estrogen, and others. Anticholinergics have traditionally been the mainstay of pharmacological treatment for urinary incontinence, particularly for urge and mixed incontinence. These drugs work by inhibiting involuntary bladder contractions, thereby reducing the frequency and urgency of urination. Despite their efficacy, anticholinergics are associated with side effects such as dry mouth, constipation, and cognitive impairment, especially in older adults. As a result,

Between June 2024 and May 2025, the rate of emergency department (ED) visits for heroin-involved nonfatal overdose in males was two per 10,000 ED visits. Meanwhile, the rate of ED visits for heroin-involved nonfatal overdose in females was 0.7 per 10,000 ED visits.

From June 2024 to May 2025, the rate of emergency department (ED) visits for fentanyl-involved nonfatal overdose among those aged between 35 and 44 was 5.3 per 10,000 ED visits, highest across all age groups. Meanwhile, the rate of ED visits for fentanyl-involved nonfatal overdose among those aged between 25 and 34 was 5.2 per 10,000 ED visits.

According to Cognitive Market Research, the global Dementia Drugs market size was USD 16215.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 7.00% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 6486.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 4864.56 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 3729.50 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.0% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 810.76 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.4%from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 324.30 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.7% from 2024 to 2031.
Alzheimer’s Disease held the highest Dementia Drugs market revenue share in 2024.

Market Dynamics of Dementia Drugs Market

Key Drivers for Dementia Drugs Market

Increased Aging Population to Increase the Demand Globally

The Dementia Drugs market has experienced growth due to the increased aging population. As life expectancy increases, the incidence of age-related neurodegenerative diseases, such as Alzheimer's and Parkinson's, is on the rise. The proportion of the world's population aged 60 years and over is projected to nearly double from 12% to 22% between 2015 and 2050. The number of people aged 80 years or older is expected to triple between 2020 and 2050. This demographic shift has created a significant and growing demand for therapeutic interventions to manage and potentially treat dementia, thereby propelling market expansion.

Escalating Prevalence of Dementia to Propel Market Growth

The Dementia Drugs market has witnessed steady growth, driven by escalating prevalence of dementia. As the global population ages, the incidence of this debilitating condition has surged, creating an urgent need for effective therapeutic interventions. This number is expected almost to double every 20 years, reaching 78 million in 2030 and 139 million in 2050. 60% of people with dementia live in low and middle-income countries. This increase in dementia cases has directly translated into heightened demand for drugs aimed at managing symptoms and potentially slowing disease progression, thereby boosting market growth.

Restraint Factor for the Dementia Drugs Market

High Cost of Dementia Drugs Production to Limit the Sales

The exorbitant cost of dementia medications presents a formidable challenge for many patients and their families. The average annual cost of dementia care in the United States, including medication, is estimated to be over $280,000. This figure underscores the financial burden imposed on individuals and caregivers. In countries with less robust healthcare systems, the cost of these medications can be even more prohibitive, limiting access to essential treatments and significantly impacting quality of life.

Impact of Covid-19 on the Dementia Drugs Market

The COVID-19 pandemic had a huge influence on the dementia medicine industry. On the one hand, the pandemic shifted healthcare resources and focus to handling the virus's acute phase, which might delay or disrupt dementia diagnosis and treatment. Furthermore, lockdowns and limitations made it difficult for patients to access healthcare services and manage their medications consistently. In contrast, the pandemic exposed the fragility of the senior population, raising awareness of dementia and its accompanying issues. This increased attention may encourage further study and development in the subject. The long-term effects of COVID-19 on dementia progression, as well as the possibility of increasing dementia cases, are still being investigated, and they may define the future of the dementia medicine market. Introduction of the Dementia Drugs Market

Dementia medicines are pharmaceuticals that are used to treat the symptoms of dementia, which is a gradual deterioration in cognitive function. These medications usually target neurotransmitters involved in memory, ...

Between June 2024 and May 2025, the rate of emergency department (ED) visits for fentanyl-involved nonfatal overdose in males was 3.5 per 10,000 ED visits. Meanwhile, the rate of ED visits for fentanyl-involved nonfatal overdose in females was 1.4 per 10,000 ED visits.

It is estimated that around *** percent of the global population uses illicit drugs. Use of illicit drugs varies by country and region as countries enact their own laws regarding such substances. Access to illicit drugs also differs by country and region and culture plays a role in how acceptable drug use is. Global drug use Worldwide, cannabis is by far the most used illicit drug, followed by opioids and amphetamines. It is estimated that around *** million people worldwide consume illegal drugs and **** million could be considered addicts or problem drug users. Drug addiction and abuse can negatively impact relationships, increases the risk of a number of diseases, and can ultimately lead to death. Opioid epidemic in the U.S. The United States has a long and complicated history with illegal drugs, once going so far as to fight a “War on Drugs”. Today, the U.S. is experiencing what has been called an opioid epidemic. This has been characterized by an increase in overdose deaths from prescription opioids, heroin and, more recently, illegally manufactured synthetic opioids, such as fentanyl. In 2021, there were ****** opioid overdose deaths in the United States.

In 2021, it was estimated that around *** million people worldwide consumed illegal drugs such as cannabis, opioids, and cocaine. Furthermore, around **** million people were thought to be problem drug users or to have a drug use disorder. Although drug use varies from country to country, drug use remains a significant problem in many parts of the world. For example, the United States is currently experiencing an opioid epidemic, with drug overdose deaths reaching record levels over the past few years. What is the most used illicit drug worldwide? The most used illicit drug worldwide is cannabis, followed by opioids, and amphetamines. High estimates suggest that around *** percent of the global population consumed cannabis in the past year as of 2021. In comparison, around *** percent of people were thought to have consumed opioids in the past year, and less than *** percent were estimated to have used amphetamines. Drug use is generally more prevalent among men than women, but this distribution varies by drug. For example, around ** percent of cocaine users worldwide are men and ** percent are women, but women account for ** percent of amphetamine users. Cannabis uses In 2021, it was estimated that around *** million people worldwide consumed cannabis at least once in the past year. The highest number of past year cannabis users at that time was found in the Americas. This may be unsurprising since Canada and many U.S. states now allow the sale and use of recreational cannabis. The market for recreational cannabis is substantial in both countries. In the United States, sales of recreational cannabis reached **** billion U.S. dollars in 2021 and are expected to grow to some ** billion U.S. dollars by the year 2026. In 2020, there were thought to be around **** million adult consumers of cannabis in the United States, with this number expected to increase to just over *** million by 2025.